The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?
Open accessAbstract
In the past decade, CHK2 has emerged as an important multifunctional player in the DNA-damage response signalling pathway. Parallel studies of the human CHEK2 gene have also highlighted its role as a candidate multiorgan tumour susceptibility gene rather than a highly penetrant predisposition gene for Li–Fraumeni syndrome. As discussed here, our current understanding of CHK2 function in tumour cells, in both a biological and genetic context, suggests that targeted modulation of the active kinase or exploitation of its loss in tumours could prove to be effective anti-cancer strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Mutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
The DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Activation of the ATM Kinase by Ionizing Radiation and Phosphorylation of p53
Canman, C. E., Lim, D.-S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., & Siliciano, J. D. (1998) · Science · doi:10.1126/science.281.5383.1677 · Cited by 2,042
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication
Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra, C., Garre’, M., Giovanni Nuciforo, P., Bensimon, A., et al. (2006) · Nature · doi:10.1038/nature05327 · Cited by 1,821
Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage
Banin, S., Moyal, L., Shieh, S.-Y., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., et al. (1998) · Science · doi:10.1126/science.281.5383.1674 · Cited by 1,797
Linkage of ATM to Cell Cycle Regulation by the Chk2 Protein Kinase
Matsuoka, S. (1998) · Science · doi:10.1126/science.282.5395.1893 · Cited by 1,322
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
A cancer family syndrome in twenty-four kindreds.
Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293
DNA Damage-Induced Activation of p53 by the Checkpoint Kinase Chk2
Hirao, A., Kong, Y.-Y., Matsuoka, S., Wakeham, A., Ruland, J., Yoshida, H., Liu, D., Elledge, S. J., & Mak, T. W. (2000) · Science · doi:10.1126/science.287.5459.1824 · Cited by 1,285
The CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
Falck, J., Mailand, N., Syljuåsen, R. G., Bartek, J., & Lukas, J. (2001) · Nature · doi:10.1038/35071124 · Cited by 1,085
Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 904
Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro
Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., & Elledge, S. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190030497 · Cited by 829
Chk2/hCds1 functions as a DNA damage checkpoint in G1by stabilizing p53
Chehab, N. H., Malikzay, A., Appel, M., & Halazonetis, T. D. (2000) · Genes & Development · doi:10.1101/gad.14.3.278 · Cited by 805
Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer
Walsh, T., Casadei, S., Coats, K. H., Swisher, E., Stray, S. M., Higgins, J., Roach, K. C., Mandell, J., Lee, M. K., Ciernikova, S., et al. (2006) · JAMA · doi:10.1001/jama.295.12.1379 · Cited by 666
Sørensen, C. S., Syljuåsen, R. G., Falck, J., Schroeder, T., Rönnstrand, L., Khanna, K. K., Zhou, B.-B., Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00048-5 · Cited by 559
CHEK2 Is a Multiorgan Cancer Susceptibility Gene
Cybulski, C., Górski, B., Huzarski, T., Masojć, B., Mierzejewski, M., Dębniak, T., Teodorczyk, U., Byrski, T., Gronwald, J., Matyjasik, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/426403 · Cited by 551
hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response
Lee, J.-S., Collins, K. M., Brown, A. L., Lee, C.-H., & Chung, J. H. (2000) · Nature · doi:10.1038/35004614 · Cited by 529
Allen, J. B., Zhou, Z., Siede, W., Friedberg, E. C., & Elledge, S. J. (1994) · Genes & Development · doi:10.1101/gad.8.20.2401 · Cited by 496
(2004) · The American Journal of Human Genetics · doi:10.1086/421251 · Cited by 471
A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast Cancer
Vahteristo, P., Bartkova, J., Eerola, H., Syrjäkoski, K., Ojala, S., Kilpivaara, O., Tamminen, A., Kononen, J., Aittomäki, K., Heikkilä, P., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/341943 · Cited by 467
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription
Takai, H., Naka, K., Okada, Y., Watanabe, M., Harada, N., Saito, S., Anderson, C. W., Appella, E., Nakanishi, M., Suzuki, H., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf506 · Cited by 436
GermlineTP53 mutations and Li-Fraumeni syndrome
Varley, J. M. (2003) · Human Mutation · doi:10.1002/humu.10185 · Cited by 430
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway
Chaturvedi, P., Eng, W. K., Zhu, Y., Mattern, M. R., Mishra, R., Hurle, M. R., Zhang, X., Annan, R. S., Lu, Q., Faucette, L. F., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202925 · Cited by 423
Hirao, A., Cheung, A., Duncan, G., Girard, P.-M., Elia, A. J., Wakeham, A., Okada, H., Sarkissian, T., Wong, J. A., Sakai, T., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.18.6521-6532.2002 · Cited by 404
Ahn, J. Y., Schwarz, J. K., Piwnica-Worms, H. M., & Canman, C. E. (2000) · PubMed · Cited by 396
Targeting the checkpoint kinases: chemosensitization versus chemoprotection
Zhou, B.-B. S., & Bartek, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1296 · Cited by 391
Chk2 activates E2F-1 in response to DNA damage
Stevens, C., Smith, L., & La Thangue, N. B. (2003) · Nature Cell Biology · doi:10.1038/ncb974 · Cited by 385
Chk2 Phosphorylation of BRCA1 Regulates DNA Double-Strand Break Repair
Zhang, J., Willers, H., Feng, Z., Ghosh, J. C., Kim, S., Weaver, D. T., Chung, J. H., Powell, S. N., & Xia, F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.2.708-718.2004 · Cited by 323
Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1
Melchionna, R., Chen, X.-B., Blasina, A., & McGowan, C. H. (2000) · Nature Cell Biology · doi:10.1038/35036406 · Cited by 311
Mutations in CHEK2 Associated with Prostate Cancer Risk
Dong, X., Wang, L., Taniguchi, K., Wang, X., Cunningham, J. M., McDonnell, S. K., Qian, C., Marks, A. F., Slager, S. L., Peterson, B. J., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/346094 · Cited by 308
A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase
Blasina, A., de Weyer, I. V., Laus, M. C., Luyten, W. H. M. L., Parker, A. E., & McGowan, C. H. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80041-4 · Cited by 303
A kinase from fission yeast responsible for blocking mitosis in S phase
Murakami, H., & Okayama, H. (1995) · Nature · doi:10.1038/374817a0 · Cited by 281
Brown, A. L., Lee, C.-H., Schwarz, J. K., Mitiku, N., Piwnica-Worms, H., & Chung, J. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3745 · Cited by 261
ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage
Chen, L., Gilkes, D. M., Pan, Y., Lane, W. S., & Chen, J. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600812 · Cited by 260
Tan, Y., Raychaudhuri, P., & Costa, R. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01068-06 · Cited by 246
PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2
Yang, S., Kuo, C., Bisi, J. E., & Kim, M. K. (2002) · Nature Cell Biology · doi:10.1038/ncb869 · Cited by 239
Li, J., Williams, B. L., Haire, L. F., Goldberg, M., Wilker, E., Durocher, D., Yaffe, M. B., Jackson, S. P., & Smerdon, S. J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00527-0 · Cited by 232
The CHEK2 gene and inherited breast cancer susceptibility
Nevanlinna, H., & Bartek, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209877 · Cited by 219
DNA damage checkpoint kinase Chk2 triggers replicative senescence
Gire, V., Roux, P., Wynford‐Thomas, D., Brondello, J., & Dulic, V. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600259 · Cited by 198
Ou, Y.-H., Chung, P.-H., Sun, T.-P., & Shieh, S.-Y. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-08-0689 · Cited by 198
Ahn, J.-Y., Li, X., Davis, H. L., & Canman, C. E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200822200 · Cited by 188
Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase
Fujimoto, H., Onishi, N., Kato, N., Takekawa, M., Xu, X. Z., Kosugi, A., Kondo, T., Imamura, M., Oishi, I., Yoda, A., et al. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401801 · Cited by 187
E2F1 Uses the ATM Signaling Pathway to Induce p53 and Chk2 Phosphorylation and Apoptosis
Powers, J. T., Hong, S., Mayhew, C. N., Rogers, P. M., Knudsen, E. S., & Johnson, D. G. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.203.2.4 · Cited by 185
Chk2 Activation and Phosphorylation-Dependent Oligomerization
Xu, X., Tsvetkov, L. M., & Stern, D. F. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.12.4419-4432.2002 · Cited by 183
p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2.
Aliouat-Denis, C.-M., Dendouga, N., Van den Wyngaert, I., Goehlmann, H., Steller, U., van de Weyer, I., Van Slycken, N., Andries, L., Kass, S., Luyten, W., et al. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0121 · Cited by 177
Checkpoint Kinase Inhibitors: SAR and Radioprotective Properties of a Series of 2-Arylbenzimidazoles
Arienti, K. L., Brunmark, A., Axe, F. U., McClure, K., Lee, A., Blevitt, J., Neff, D. K., Huang, L., Crawford, S., Pandit, C. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0495935 · Cited by 175
Characterization of Tumor-associated Chk2 Mutations
Wu, X., Webster, S. R., & Chen, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009727200 · Cited by 175
The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe
Castedo, M., Perfettini, J.-L., Roumier, T., Yakushijin, K., Horne, D., Medema, R., & Kroemer, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207573 · Cited by 175
CHEK2 variant I157T may be associated with increased breast cancer risk
Kilpivaara, O., Vahteristo, P., Falck, J., Syrjäkoski, K., Eerola, H., Easton, D., Bartkova, J., Lukas, J., Heikkilä, P., Aittomäki, K., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20299 · Cited by 163
Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.
Lee, S. B., Kim, S. H., Bell, D. W., Wahrer, D. C. R., Schiripo, T. A., Jorczak, M. M., Sgroi, D. C., Garber, J. E., Li, F. P., Nichols, K. E., et al. (2001) · PubMed · Cited by 160
A Novel Founder CHEK2 Mutation is Associated with Increased Prostate Cancer Risk
Cybulski, C., Huzarski, T., Górski, B., Masojć, B., Mierzejewski, M., Dębniak, T., Gliniewicz, B., Trubicka, J., Złowocka, E., Kurzawski, G., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0341 · Cited by 158
Bahassi, E. M., Conn, C. W., Myer, D. L., Hennigan, R. F., McGowan, C. H., Sánchez, Y., & Stambrook, P. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205850 · Cited by 157
Polo-like Kinase 1 and Chk2 Interact and Co-localize to Centrosomes and the Midbody
Tsvetkov, L. M., Xu, X., Li, J., & Stern, D. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211202200 · Cited by 156
The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer Cells
Jallepalli, P. V., Lengauer, C., Vogelstein, B., & Bunz, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213159200 · Cited by 154
Matthews, D. J., Yakes, M., Chen, J., Tadano, M., Bornheim, L. M., Clary, D. O., Tai, A., Wagner, J. M., Miller, N., Kim, Y. D., et al. (2007) · Cell Cycle · doi:10.4161/cc.6.1.3699 · Cited by 153
Apoptosis Associated with Deregulated E2F Activity Is Dependent on E2F1 and Atm/Nbs1/Chk2
Rogoff, H. A., Pickering, M., Frame, F. M., Debatis, M. E., Sánchez, Y., Jones, S. N., & Kowalik, T. F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2968-2977.2004 · Cited by 151
Lee, C. H., & Chung, J. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104414200 · Cited by 150
CHEK2 variants associate with hereditary prostate cancer
Seppälä, E. H., Ikonen, T., Mononen, N., Autio, V., Rökman, A., Matikainen, M. P., Tammela, T. L. J., & Schleutker, J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601425 · Cited by 147
Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation.
Schwarz, J. K., Lovly, C. M., & Piwnica-Worms, H. M. (2003) · PubMed · Cited by 147
Bruno, T., Nicola, F. D., Iezzi, S., Lecis, D., D’Angelo, C., Padova, M. D., Corbi, N., Dimiziani, L., Zannini, L., Jekimovs, C., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.012 · Cited by 145
Shaag, A., Walsh, T., Renbaum, P., Kirchhoff, T., Nafa, K., Shiovitz, S., Mandell, J. B., Welcsh, P. L., Lee, M. K., Ellis, N. A., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi052 · Cited by 143
Jack, M. T., Woo, R. A., Hirao, A., Cheung, A., Mak, T. W., & Lee, P. W. K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152053599 · Cited by 140
DNA-dependent Acetylation of p53 by the Transcription Coactivator p300
Dornan, D., Shimizu, H., Perkins, N. D., & Hupp, T. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211460200 · Cited by 138
Trans‐activation of the DNA‐damage signalling protein kinase Chk2 by T‐loop exchange
Oliver, A. W., Paul, A., Boxall, K. J., Barrie, S. E., Aherne, G. W., Garrett, M. D., Mittnacht, S., & Pearl, L. H. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601209 · Cited by 136
Self-citationSchutte, M. E. M., Seal, S., Barfoot, R., Meijers-Heijboer, H. E. J., Wasielewski, M., Evans, D. G., Eccles, D., Meijers, C., Lohman, F. P., Klijn, J. G. M., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/373965 · Cited by 136
Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia
Rudd, M. F., Sellick, G. S., Webb, E. L., Catovsky, D., & Houlston, R. S. (2006) · Blood · doi:10.1182/blood-2005-12-5022 · Cited by 135
Zhuang, J., Zhang, J., Willers, H., Wang, H., Chung, J. H., van Gent, D. C., Hallahan, D. E., Powell, S. N., & Xia, F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3278 · Cited by 132
Kohn, E. A., Yoo, C. J., & Eastman, A. R. (2003) · PubMed · Cited by 128
Breast cancer predisposing alleles in Poland
Górski, B., Cybulski, C., Huzarski, T., Byrski, T., Gronwald, J., Jakubowska, A., Stawicka, M., Grodecka-Gazdecka, S., Szwiec, M., Urbański, K., et al. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-1409-1 · Cited by 128
Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3
LeBron, C., Chen, L., Gilkes, D. M., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601032 · Cited by 122
Wang, H., Chou, W., Shieh, S.-Y., & Shen, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3270 · Cited by 122
Schmidt, M. K., Tollenaar, R. A. �. �., Kemp, S. R. M., Broeks, A., Cornelisse, C. J., Smit, V. T. H. B. M., Peterse, J. L., van Leeuwen, F. E., & Veer, L. V. ‘. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3024 · Cited by 121
Falck, J., Lukas, C., Protopopova, M., Lukas, J., Selivanova, G., & Bártek, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204811 · Cited by 117
Kilpivaara, O., Bártková, J., Eerola, H., Syrjäkoski, K., Vahteristo, P., Lukas, J., BLOMQVIST, C. P., Holli, K., Heikkilä, P., Sauter, G., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20638 · Cited by 116
Cybulski, C., Wokołorczyk, D., Huzarski, T., Byrski, T., Gronwald, J., Górski, B., Dębniak, T., Masojć, B., Jakubowska, A., Gliniewicz, B., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.044974 · Cited by 115
Wei, J., Chou, Y., Ou, Y.-H., Yeh, Y.-H., Tyan, S., Sun, T.-P., Shen, C., & Shieh, S.-Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410152200 · Cited by 114
de Bock, G. H., Schutte, M., Krol-Warmerdam, E. M. M., Seynaeve, C., Blom, J., Brekelmans, C. T. M., Meijers-Heijboer, H. E. J., van Asperen, C. J., Cornelisse, C. J., Devilee, P., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.019737 · Cited by 114
A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland
Cybulski, C., Wokołorczyk, D., Huzarski, T., Byrski, T., Gronwald, J., Górski, B., Dębniak, T., Masojć, B., Jakubowska, A., van de Wetering, T., et al. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9320-y · Cited by 113
Oldenburg, R. A., Kroeze‐Jansema, K., Kraan, J., Morreau, H. M., Klijn, J. G. M., Hoogerbrugge, N., Ligtenberg, M. J. L., van Asperen, C. J., Vasen, H. F. A., Meijers, C., et al. (2003) · PubMed · Cited by 112
The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase
Oliva-Trastoy, M., Berthonaud, V., Chevalier, A., Ducrot, C., Marsolier‐Kergoat, M., Mann, C., & Leteurtre, F. (2006) · Oncogene · doi:10.1038/sj.onc.1209927 · Cited by 111
Xiao, Z., Xue, J., Sowin, T. J., & Zhang, H. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0077 · Cited by 110
Varley, J. M., Thorncroft, M. R., McGown, G., Appleby, J. E., Kelsey, A. M., Tricker, K. J., Evans, D. G., & Birch, J. M. (1997) · Oncogene · doi:10.1038/sj.onc.1201041 · Cited by 105
Regulation of CHK2 by DNA-dependent Protein Kinase
Li, J., & Stern, D. F. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412445200 · Cited by 104
Questioning the Role of Checkpoint Kinase 2 in the p53 DNA Damage Response
Ahn, J., Urist, M., & Prives, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213185200 · Cited by 99
Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy
Lord, C. J., Garrett, M. D., & Ashworth, A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1269 · Cited by 99
Self-citationMiller, C. W., Ikezoe, T., Krug, U. O., Hofmann, W., Tavor, S., Vegesna, V. R., Tsukasaki, K., Takeuchi, S., & Koeffler, H. P. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1207 · Cited by 98
Alternative splicing and mutation status of CHEK2 in stage III breast cancer
Staalesen, V., Falck, J., Geisler, S. B., Bártková, J., Børresen‐Dale, A., Lukas, J., Lillehaug, J. R., Bártek, J., & Lønning, P. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207928 · Cited by 95
Limited relevance of the CHEK2 gene in hereditary breast cancer
Dufault, M. R., Betz, B., Wappenschmidt, B., Hofmann, W., Bandick, K., Golla, A., Pietschmann, A., Nestle-Krämling, C., Rhiem, K., Hüttner, C., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20073 · Cited by 94
Association of two mutations in the CHEK2 gene with breast cancer
Bogdanova, N. V., Enβen‐Dubrowinskaja, N., Feshchenko, S., Lazjuk, G. I., Rogov, Y., Dammann, O., Bremer, M., Karstens, J. H., Sohn, C., & Dörk, T. (2005) · International Journal of Cancer · doi:10.1002/ijc.21022 · Cited by 93
ATR dependent activation of Chk2
Wang, X. Q., Redpath, J. L., Fan, S. T., & Stanbridge, E. J. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20700 · Cited by 93
Concomitant inactivation of p53 and Chk2 in breast cancer
Sullivan, A., Yuille, M., Repellin, C., Reddy, A., Reelfs, O., Bell, A., Dunne, B., Gusterson, B. A., Osin, P., Farrell, P. J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205207 · Cited by 91
Carlessi, L., Buscemi, G., Larson, G., Hong, Z., Wu, J. Z., & Delia, D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0567 · Cited by 89
CHEK2 I157T associates with familial and sporadic colorectal cancer
Kilpivaara, O., Alhopuro, P., Vahteristo, P., Aaltonen, L. A., & Nevanlinna, H. A. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.038331 · Cited by 86
Ahn, J., & Prives, C. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208321200 · Cited by 82
Tort, F., Hernandez, S. F., Beà, S., Martı́nez, A., Esteller, M., Herman, J. G., Puig, X., Camacho, E., Sánchez, M., Nayach, I., et al. (2002) · Blood · doi:10.1182/blood-2002-04-1078 · Cited by 81
Haruki, N., Saito, H., Tatematsu, Y., Konishi, H., Harano, T., Masuda, A., Osada, H., Fujii, Y., & Takahashi, T. (2000) · PubMed · Cited by 80
Yu, Q., Rose, J. H. L., Zhang, H., & Pommier, Y. G. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02756-9 · Cited by 80
Excess Risk for Contralateral Breast Cancer in CHEK2*1100delC Germline Mutation Carriers
Broeks, A., de Witte, L. D., Nooijen, A., Huseinovic, A., Klijn, J. G. M., van Leeuwen, F. E., Russell, N. S., & Veer, L. J. V. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000010697.49896.03 · Cited by 80
Sodha, N., Williams, R., Mangion, J., Bullock, S. L., Yuille, M., & Eeles, R. A. (2000) · Science · doi:10.1126/science.289.5478.359a · Cited by 80
Self-citationUncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case–control study
Brennan, P., McKay, J., Moore, L. E., Zaridze, D. G., Mukeria, A., Szeszenia‐Dabrowska, N., Lissowska, J., Rudnai, P., Fabiánová, E., Mateș, D., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm127 · Cited by 80
Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale
Pommier, Y. G., Sordet, O., Rao, A. U. K., Zhang, H., & Kohn, K. W. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612054546716 · Cited by 79
Autophosphorylation of Checkpoint Kinase 2 at Serine 516 Is Required for Radiation-induced Apoptosis
Wu, X., & Chen, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303795200 · Cited by 72
Sodha, N., Bullock, S. L., Taylor, R., Mitchell, G., Guertl‐Lackner, B., Williams, R. D., Bevan, S., Bishop, K., McGuire, S., Houlston, R. S., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600637 · Cited by 72
Self-citationPotent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine
Sharma, V., & Tepe, J. J. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.05.079 · Cited by 67
Activated Checkpoint Kinase 2 Provides a Survival Signal for Tumor Cells
Ghosh, J. C., Dohi, T., Raskett, C. M., Kowalik, T. F., & Altieri, D. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3095 · Cited by 66
Honrado, E., Osório, A., Palacios, J., Milne, R. L., Sánchez, L., Dı́ez, O., Cazorla, A., Syrjäkoski, K., Huntsman, D. D., Heikkilä, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3698 · Cited by 65
CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors
Szymańska-Pasternak, J., Szymanska, A., Mędrek, K., Имянитов, Е. Н., Cybulski, C., Górski, B., Magnowski, P., Dziuba, I., Gugała, K., Dębniak, B., et al. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.05.040 · Cited by 64
Mutation analysis of the CHK2 gene in breast carcinoma and other cancers
Ingvarsson, S., Sigbjornsdottir, B. I., Huiping, C., Hafsteinsdottir, S. H., Ragnarsson, G., Barkardottir, R. B., Arason, A., Egilsson, V., & Bergthorsson, J. T. (2002) · Breast Cancer Research · doi:10.1186/bcr435 · Cited by 63
Bahassi, E. M., Myer, D. L., McKenney, R. J., Hennigan, R. F., & Stambrook, P. J. (2006) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2005.12.002 · Cited by 63
Jobson, A. G., Cardellina, J. H., Scudiero, D. A., Kondapaka, S. B., Zhang, H., Kim, H., Shoemaker, R. H., & Pommier, Y. G. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.035832 · Cited by 62
Bihan-Benjamin, C. L., Moutou, C., Brugières, L., Feunteun, J., & Bonaïti‐Pellié, C. (1995) · Genetic Epidemiology · doi:10.1002/gepi.1370120103 · Cited by 61
Friedrichsen, D. M., Malone, K. E., Doody, D. R., Daling, J. R., & Ostrander, E. A. (2004) · Breast Cancer Research · doi:10.1186/bcr933 · Cited by 60
Increasing evidence that germline mutations inCHEK2do not cause Li-Fraumeni syndrome
Sodha, N., Houlston, R. S., Bullock, S. L., Yuille, M., Chu, C., Turner, G., & Eeles, R. A. (2002) · Human Mutation · doi:10.1002/humu.10136 · Cited by 60
Self-citationMorgan, M. A., Parsels, L. A., Parsels, J. D., Lawrence, T. S., & Maybaum, J. (2006) · Cell Cycle · doi:10.4161/cc.5.17.3184 · Cited by 59
Genetic and Epigenetic Analysis of CHEK2 in Sporadic Breast, Colon, and Ovarian Cancers
Williams, L. H., Choong, D., Johnson, S. A. S., & Campbell, I. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1770 · Cited by 58
Birch, J. M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00383-g · Cited by 57
DNA Damage-Induced Cell Cycle Regulation and Function of Novel Chk2 Phosphoresidues
Buscemi, G., Carlessi, L., Zannini, L., Lisanti, S., Fontanella, E., Canevari, S., & Delia, D. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00534-06 · Cited by 56
Bernstein, J. L., Teraoka, S. N., John, E. M., Andrulis, I. L., Knight, J. A., Lapinski, R. H., Olson, E. R., Wolitzer, A. L., Seminara, D., Whittemore, A. S., et al. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0557 · Cited by 54
Chen, C.-R., Wang, W., Rogoff, H. A., Li, X., Mang, W., & Li, C. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0677 · Cited by 52
Promyelocytic Leukemia Activates Chk2 by Mediating Chk2 Autophosphorylation
Yang, S., Jeong, J., Brown, A. L., Lee, C., Pandolfi, P. P., Chung, J. H., & Kim, M. K. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604391200 · Cited by 51
Sodha, N., Mantoni, T. S., Tavtigian, S. V., Eeles, R. A., & Garrett, M. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1990 · Cited by 51
Self-citationAberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer
Bártková, J., Guldberg, P., Grønbæk, K., Koed, K., Primdahl, H., Møller, K., Lukas, J., Orntoft, T. F., & Bártek, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207878 · Cited by 49
Mutations of Chk2 in primary hematopoietic neoplasms
Hangaishi, A., Ogawa, S., Qiao, Y., Wang, L., Hosoya, N., Yuji, K., Imai, Y., Takeuchi, K., Miyawaki, S., & Hirai, H. (2002) · Blood · doi:10.1182/blood.v99.8.3075 · Cited by 48
kConFab Investigators, Jekimovs, C., Chen, X., Arnold, J. M., Gatei, M. H., Richard, D. J., Spurdle, A. B., Khanna, K. K., & Chenevix‐Trench, G. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602381 · Cited by 44
Characterization ofCHEK2 mutations in prostate cancer
Wu, X., Dong, X., Liu, W., & Chen, J. (2006) · Human Mutation · doi:10.1002/humu.20321 · Cited by 41
Identification of novel, selective and potent Chk2 inhibitors
Larson, G., Yan, S., Chen, H., Rong, F., Hong, Z., & Wu, J. Z. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.09.067 · Cited by 41
Jack, M. T., Woo, R. A., Motoyama, N., Takai, H., & Lee, P. W. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309917200 · Cited by 39
CHEK2-Positive Breast Cancers in Young Polish Women
Cybulski, C., Górski, B., Huzarski, T., Byrski, T., Gronwald, J., Dębniak, T., Wokołorczyk, D., Jakubowska, A., Kowalska, E., Oszurek, O., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0158 · Cited by 39
Sturgeon, C. M., Knight, Z. A., Shokat, K. M., & Roberge, M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0358 · Cited by 39
Analysis of CHK2 in vulval neoplasia
Reddy, A., Yuille, M., Sullivan, A., Repellin, C. E., Bell, A., TIDY, J. A., Evans, D. J., Farrell, P. J., Gusterson, B. A., Gasco, M., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600131 · Cited by 38
Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer
Złowocka, E., Cybulski, C., Górski, B., Dębniak, T., Słojewski, M., Wokołorczyk, D., Serrano‐Fernández, P., Trubicka, J., van de Wetering, T., Sikorski, A., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23099 · Cited by 36
King, J. B., Gross, J., Lovly, C. M., Rohrs, H. W., Piwnica-Worms, H. M., & Townsend, R. R. (2006) · Analytical Chemistry · doi:10.1021/ac051520l · Cited by 34
Liang, X., Reed, E., & Yu, J. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.17.5.703 · Cited by 32
Stability of Checkpoint Kinase 2 Is Regulated via Phosphorylation at Serine 456
Kass, E. M., Ahn, J., Tanaka, T., Freed-Pastor, W. A., Keezer, S. M., & Prives, C. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704642200 · Cited by 31
van Puijenbroek, M., van Asperen, C. J., van Mil, A., Devilee, P., van Wezel, T., & Morreau, H. M. (2005) · The Journal of Pathology · doi:10.1002/path.1764 · Cited by 28
CHEK2 mutations in primary glioblastomas
Sallinen, S., konen, T., Haapasalo, H. K., & Schleutker, J. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-5953-7 · Cited by 26
Epistatic Relationship between the Cancer Susceptibility Genes CHEK2 and p27
Cybulski, C., Gliniewicz, B., Sikorski, A., Kładny, J., Huzarski, T., Gronwald, J., Byrski, T., Dębniak, T., Górski, B., Jakubowska, A., et al. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0566 · Cited by 22
Analysis of CHK2 in patients with myelodysplastic syndromes
Aktaş, D., Arno, M. J., Rassool, F. V., & Mufti, G. J. (2002) · Leukemia Research · doi:10.1016/s0145-2126(02)00075-9 · Cited by 20
The CHEK2*1100delC mutation has no major contribution in oesophageal carcinogenesis
Koppert, L. B., Schutte, M. E. M., Abbou, M., Tilanus, H. W., & Dinjens, W. N. M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601551 · Cited by 11
Cited by
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
Metadata
- Authors
- Antoni, L., Sodha, N., Collins, I., & Garrett, M. D.
- Venue
- Nature Reviews Cancer
- Published
- 2007-12
- Volume
- 7
- Issue
- 12
- Pages
- 925-936
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2054576158
- Cited by
- 288
- References
- 145
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.